Within the United States, below represents our currently available products. Please note the product information on this site is intended for U.S. residents only, and product labeling may vary from labeling in different countries.
Contacts
Please find contacts below for further information relating to our products, including:
Reporting Side Effects
You are encouraged to report side effects to the U.S. Food and Drug Administration. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Information for Colorado Prescribers
Wholesale Acquisition Cost Information
Our Products
See links below for Anzupgo® (delgocitinib) cream 2% Prescribing Information
Click Here for Dovonex® (calcipotriene) Cream, 0.005% Prescribing Information
Dovonex® (calcipotriene) Cream, 0.005%
Click Here for Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% Prescribing Information
Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%
Click Here for Finacea® (azelaic acid) Foam, 15% Prescribing Information
Finacea® (azelaic acid) Foam, 15%
Click Here for Finacea® (azelaic acid) Gel, 15% Prescribing Information
Finacea® (azelaic acid) Gel, 15%
Protopic® (tacrolimus) Ointment, 0.03%and 0.1%
LEO Pharma Inc. has discontinued the sale and marketing of Protopic® in the United States
Taclonex’ (calcipotriene and betamethasone dipropionate) Topical Suspension
Taclonex” (calcipotriene and betamethasone dipropionate) Ointment
The LEO Pharma logo, Adbry®, Anzupgo®, Dovonex®, Enstilar®, Finacea®, Protopic®, Spevigo® and Taclonex® are registered trademarks of LEO Pharma A/S.
@2026 LEO Pharma Inc. All rights reserved. MAT 95748